Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Eli Lilly has emerged as a popular growth ... used to treat chronic weight management and diabetes. While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility. Evan ...

While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what Lilly's business looks like beyond weight loss ...